This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Despite recent declines, data shows that 8.5% of middle school (grades 6-8) and 18.1% of high school (grades 9-12) students in the United States (US) used electronic nicotine delivery systems (ENDS; variously known as vaping, electronic \[e\]-cigarettes, e-cigs, mods, and tank systems that contain nicotine). Use of any tobacco product during adolescence increases risk for lifelong nicotine addiction. ENDS use, in particular, leads to severe asthma attacks, e-cigarette or vaping product use-associated lung injury (EVALI), exposure to multiple lung irritants, including volatile organic compounds, and lasting harm to adolescent brain development. Despite evidence of potential long-term harms from ENDS, to date there have been limited evidence-based therapeutic options for ENDS cessation for adolescents and young adults. Traditional methods for delivering adolescent ENDS cessation interventions (e.g., quitlines and clinics) have limited reach. QuitQuest utilizes Acceptance and Commitment Therapy (ACT), a psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility, reduce distress, and promote behavior change through mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. The SFTQV program is based on the US Clinical Practice Guidelines, offering practical advice and support via an app delivery format. The QuitQuest app may work better than the SFTQV app in increasing vape quit rates among teens.
Age 13 to 17
Used ENDS at least weekly in the past 30 days
Wants to quit ENDS within the next 30 days
If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
Exclusion criteria are the reverse of the inclusion criteria
Parallel
Smartphone Application-based Intervention
BehavioralUse QuitQuest app
Smartphone Application-based Intervention
BehavioralUse SFTQV app
Survey Administration
Other interventionAncillary studies
Interview
Other interventionAncillary studies
Self-reported 30-day point prevalence abstinence (PPA) from electronic nicotine delivery systems (ENDS) use
Biochemical verification will be used to validate self-reported abstinence among participants who opt in at baseline and complete testing. In the primary intent-to-treat analysis, participants with missing 6-month self-reported outcome data will be classified as vaping. The primary missing=vaping outcome is based on self-reported 30-day ENDS use status, not on completion of biochemical verification. Participants who self-report abstinence but do not complete biochemical testing will not be automatically classified as vaping solely because biochemical verification is missing. The primary logistic regression model will adjust for the stratification factors used in randomization to appropriately account for study design, thereby improving the estimation of standard errors and increasing the validity of significance tests for the main treatment effect.
Self-reported 30-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Self-reported 24-hour PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Self-reported 7-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Self-reported 30-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Click on the lead sponsor to view all of their trials.
Fred Hutchinson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Endeavor Health
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
